Selection of peptide ligands for the antimucin core antibody C595 using phage display technology: definition of candidate epitopes for a cancer vaccine
Clinical Molecular Pathology · 1995
DOI: 10.1136/mp.48.3.m136 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Molecular Pathology, 1995. Verfasst von P Laing und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Molecular and Clinical Immunology, Clinical Laboratory Science Dept, University Hospital, Queens Medical Centre, Nottingham NG7 2UH. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Division of Molecular and Clinical Immunology, Clinical Laboratory Science Dept, University Hospital, Queens Medical Centre, Nottingham NG7 2UH.
Zitieren
APA
Laing, P., Tighe, P., Kwiatkowski, E., Milligan, J., Price, M., & Sewell, H. (1995). Selection of peptide ligands for the antimucin core antibody C595 using phage display technology: definition of candidate epitopes for a cancer vaccine. Clinical Molecular Pathology. https://doi.org/10.1136/mp.48.3.m136
Vancouver
Laing P, Tighe P, Kwiatkowski E, Milligan J, Price M, Sewell H. Selection of peptide ligands for the antimucin core antibody C595 using phage display technology: definition of candidate epitopes for a cancer vaccine. Clinical Molecular Pathology. 1995. doi:10.1136/mp.48.3.m136
BibTeX
@article{Laing1995,
author = {Laing, P and Tighe, P and Kwiatkowski, E and Milligan, J and Price, M and Sewell, H},
title = {Selection of peptide ligands for the antimucin core antibody C595 using phage display technology: definition of candidate epitopes for a cancer vaccine},
journal = {Clinical Molecular Pathology},
year = {1995},
doi = {10.1136/mp.48.3.m136}
}
EUVIMED